Loading stock data…
NTRA
$194.24-25.58 (-11.64%)
Market ClosedLast close May 8
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Natera, Inc. in the Healthcare sector is trading at $194.24. The stock is currently 24% below its 52-week high of $256.36, remaining 2.2% below its 200-day moving average. Technical signals show neutral RSI of 42 and bullish MACD crossover, explaining why NTRA maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$194.24
Potential Upside
5%
Whystock Fair Value$203.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Mean target$258.00+32.8%
Range$190.00 – $300.00
Fundamentals
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.79%
Volume
Today's trading volume
3.45M
Recent News
Natera Q1 Earnings Call Highlights
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women’s health and another record quarter
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of -5.26% and +13.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Natera NTRA Q1 2026 Earnings Call Transcript
Michael Brophy: Thank you for joining our conference call to discuss the results of our first quarter of 2026. On the line, I am joined by Steve Chapman, our CEO, Solomon Moshkevich, President, Clinical Diagnostics, and Alexey Aleshin, General Manager of Oncology and our Chief Medical Officer. Starting on Slide 2, during the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies and expected results, opportunities and strategies, and expectations for current and future products, including product capabilities, expected release dates, reimbursement coverage, and related effects on our financial and operating results.
Natera’s (NASDAQ:NTRA) Q1 CY2026 Sales Top Estimates
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2026, with sales up 38.8% year on year to $696.6 million. Its GAAP loss of $0.60 per share was 8.4% below analysts’ consensus estimates.